Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DBV Enters Whooping Cough Booster Vax Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

DBV Enters Whooping Cough Booster Vax Pact

Will combine BioNet's Pertussis Toxin with DBV's Viaskin technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DBV Technologies has entered into a collaboration agreement with BioNet-Asia Co. and the University of Geneva (UNIGE) to develop a whooping cough (pertussis) booster vaccine. The clinical proof-of-concept product candidate will combine BioNet’s recombinant non-toxic Pertussis Toxin (rPT) with DBV’s Viaskin technology, which allows for the epicutaneous delivery of the antigen without an adjuvant.

The R&D collaboration will measure the specific immunity and protective responses elicited by a Viaskin pertussis antigens boost in a Bordetella pertussis respiratory model. A clinical study program will be initiated in 2H14 to evaluate the boosting influence of recombinant non-toxic pertussis toxin delivered by Viaskin in a Phase I, proof-of-concept, study that will assess the safety and immunogenicity.

Dr. Pierre-Henri Benhamou, chairman and chief executive officer of DBV Technologies, said, “We are honored to collaborate with the team of the University of Geneva on this very exciting new application of the Viaskin Platform for booster vaccination. We consider it a privilege to be the first European partner of BioNet in the frame of such a trustful collaboration with the BioNet team. With BioNet’s experience in recombinant vaccine antigens, coupled with DBV’s epicutaneous delivery method and the University of Geneva’s vaccinology track record, this collaboration could open a new field to the delivery of vaccines, allowing to increase compliance and help control diseases such as pertussis that are unfortunately on the rise again.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics